Ex vivo drug response profiling detects recurrent sensitivity patterns in drug-resistant acute lymphoblastic leukemia.
about
In silico and preclinical drug screening identifies dasatinib as a targeted therapy for T-ALL.Image-based ex-vivo drug screening for patients with aggressive haematological malignancies: interim results from a single-arm, open-label, pilot study.Drug-perturbation-based stratification of blood cancer.Functional precision cancer medicine-moving beyond pure genomics.TP53 in adult acute lymphoblastic leukemia.New targeted therapies for relapsed pediatric acute lymphoblastic leukemia.
P2860
Ex vivo drug response profiling detects recurrent sensitivity patterns in drug-resistant acute lymphoblastic leukemia.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
2017年论文
@zh
2017年论文
@zh-cn
name
Ex vivo drug response profilin ...... acute lymphoblastic leukemia.
@en
type
label
Ex vivo drug response profilin ...... acute lymphoblastic leukemia.
@en
prefLabel
Ex vivo drug response profilin ...... acute lymphoblastic leukemia.
@en
P2093
P2860
P50
P1433
P1476
Ex vivo drug response profilin ...... t acute lymphoblastic leukemia
@en
P2093
Andreas E Kulozik
Anna Rinaldi
Arend Von Stackelberg
Bill H Chang
Blerim Marovca
Cornelia Eckert
Ernesto Diaz-Flores
Gnana P Balasubramanian
Gunnar Cario
Jeffrey W Tyner
P2860
P304
P356
10.1182/BLOOD-2016-09-738070
P407
P50
P577
2017-01-25T00:00:00Z